Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Moleculin Biotech (MBRX) Return on Equity (2016 - 2025)

Moleculin Biotech (MBRX) has 10 years of Return on Equity data on record, last reported at 1.58% in Q3 2025.

  • For Q3 2025, Return on Equity rose 311.0% year-over-year to 1.58%; the TTM value through Sep 2025 reached 1.58%, up 311.0%, while the annual FY2024 figure was 1.24%, 56.0% down from the prior year.
  • Return on Equity reached 1.58% in Q3 2025 per MBRX's latest filing, up from 4.95% in the prior quarter.
  • Across five years, Return on Equity topped out at 1.58% in Q3 2025 and bottomed at 4.95% in Q2 2025.
  • Average Return on Equity over 5 years is 0.87%, with a median of 0.64% recorded in 2023.
  • The widest YoY moves for Return on Equity: up 311bps in 2025, down -374bps in 2025.
  • A 5-year view of Return on Equity shows it stood at 0.29% in 2021, then plummeted by -92bps to 0.55% in 2022, then plummeted by -56bps to 0.86% in 2023, then tumbled by -113bps to 1.82% in 2024, then soared by 187bps to 1.58% in 2025.
  • Per Business Quant database, its latest 3 readings for Return on Equity were 1.58% in Q3 2025, 4.95% in Q2 2025, and 2.05% in Q1 2025.